BRING ON THE NEXT DRUG and EMA /ESTIMATES not factored in ..and you could be looking
at another JAZZ like Stock by this time NEXT year. I believe TRACTION of superior product takes hold in a big way as (MOST) phys do not want to re-address nor take on liability issues . REIMBURSEMENT is not a problem and potential Longer term costs w/complications will certainly be a front burner decision.
May not be alot of reaction to quarter numbers either up or down .// but anticpation of next quarter numbers will take it to 18-21 area.